RT Journal Article
SR Electronic
T1 Profile of Mucormycosis Cases from a Network of Hospitals in North India Amidst COVID-19 Pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.25.21262404
DO 10.1101/2021.08.25.21262404
A1 Budhiraja, Sandeep
A1 Aggarwal, Mona
A1 Mahajan, Monica
A1 Indrayan, Abhaya
A1 Jha, Vinita
A1 Mittal, Ambrish
A1 Sachdeva, Sanjay
A1 Mrig, Sumit
A1 Jain, Anurag
A1 Gera, Ravinder
A1 Aggarwal, Rahul
A1 Kalra, Suven
A1 Ramalingam, WVPS
A1 Deka, Anupal
A1 Das, Arjun
A1 Jijina, D
A1 Mansingh, Ajit
A1 Singhal, Anuj
A1 Reddi, Rajashekhar
A1 Aggarwal, Puneet
A1 Kumar, Mukesh
A1 Mukherjee, JD
A1 Nangia, Vivek
A1 Lall, Ajay
A1 Singh, Omender
A1 Dewan, Arun
A1 Jain, Ajay
A1 Shrivastava, Gita G
A1 Bhattacharjee, Mala
A1 Nihalani, Meena
A1 Kumar, Manoj
A1 Jain, Meenakshi
A1 Mehra, Mukesh
A1 Arora, Vijay
A1 Mehta, Viresh Prashant
A1 Bhalla, Dilip
A1 Batra, Amit
A1 Gupta, Rajesh
A1 Kumar, Vivek
A1 Dua, Sanjeev
A1 Pandey, Praveen
A1 Singh, Y P
A1 Mathur, Mohit
A1 Singh, Ashok
A1 Arora, Sanjeev
A1 Gupta, Ajay Kumar
A1 Choudhary, Pankaj Nand
A1 Singh, Manoj
A1 Kaul, Namita
A1 Pathak, Sitla Prasad
A1 Joshi, Sharad
A1 Gupta, Manish
A1 Mishra, Rajesh
A1 Joshi, Alok
A1 Aggarwal, Manoj
A1 Gupta, Rajiv
A1 Boobna, Vandana
A1 Chhabra, Yogesh Kumar
A1 Chugh, Inder Mohan
A1 Garg, Sandeep
A1 Mittal, Vikas
A1 Sood, Neha
A1 Kumar, Anil
A1 Pande, Rajesh Kumar
A1 Singh, V P
A1 Khan, Iram
A1 Garg, Nitin
A1 Tyagi, Puneet
A1 Belwal, Shantanu
A1 Roy, Anup Kumar
A1 Bhasin, Deepak
A1 Pandove, Sachin
A1 Bahl, Ravikant
A1 Soni, Prateek
YR 2021
UL http://medrxiv.org/content/early/2021/08/28/2021.08.25.21262404.abstract
AB Incidence of mucormycosis suddenly surged in India after the second wave of COVID-19. This is a crippling disease and needs to be studied in detail to understand the disease, its course, and the outcomes.Between 1st March and 15th July 2021, our network of hospitals in North India received a total of 155 cases of COVID-associated mucormycosis cases as all of them reported affliction by COVID-19 earlier or concurrent. Their records were retrieved from the Electronic Health Records system of the hospitals and their demographics, clinical features, treatments, and outcomes were studied. More than 80% (125 cases) had proven disease and the remaining 30 were categorized as ‘possible’ mucormycosis as per the EORTC criteria.More than two-thirds (69.0%) of the cases were males and the mean age was 53 years for either sex. Nearly two-thirds (64.5%) had symptoms of nose and jaws and 42.6% had eye involvement. Some had multiple symptoms. As many as 78.7% had diabetes and 91.6% gave history of use of steroids during COVID-19 treatment. The primary surgery was functional endoscopic sinus surgery (FESS) (83.9%). Overall mortality was 16.8%, which is one-and-a-half times the mortality in hospitalized COVID-19 patients in the corresponding population. Occurrence of mucormycosis was associated with diabetes and use of steroids, but mortality was not associated with either of them. Cases undergoing surgery and on antifungal had steeply lower mortality (11.9% vs. 50.0%, P < 0.001) than those who were exclusively on antifungal drugs. Treatment by different drugs did not make much of a difference in mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any financial contribution from any funding agency/source.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Ethics Committee, Max Super Speciality Hospital (A unit of Devki Devi Foundation), Address : Service Floor, Office of Ethics Committee, East Block, next to Conference Room, Max Super Speciality Hospital, Saket (A unit of Devki Devi Foundation), 2, Press Enclave Road, Saket, New Delhi 110017 vide ref. no. BHR/RS/MSSH/DDF/SKT-2/IEC/IM/21-19 dated 19th July2021. The IEC provided no objection and approved the publication of this manuscript. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a retrospective, observational, multi-centre study that included all the cases recorded as mucormycosis either at discharge or at death, between 1st March 2021 and 15th July 2021 in our network of hospitals in North India. Their records were retrieved from the Electronic Health Records system and their demographic and clinical profile, the hospital course, and the outcome were noted.